How Can Your Preclinical Oncology Models Influence and Translate into Clinical Success?
The 8th annual PREDiCT: Tumour Models London will return this December with a fresh speaker faculty to help you benchmark your oncology model selection strategy and target validation. With the rise of immuno-oncology, model requirements, target validation and the importance of tumour micro-environment are key to clinical success. The 3-days summit will provide you with real world data from a selected model experts, including Merck Healthcare KGaA, MedImmune, Kymab, Leiden University, Basilea Pharmaceutica for practical insights.
Unmissable Case Studies:
*Unique PDX models to advance liquid-biopsy research and immunotherapy (Rabin Medical Center)
*Assessment of different humanised mouse models for the evaluation of cancer immunotherapies (Sanofi)
*Innovative models with increased clinical relevance and predictive value for in vivo profiling of cancer immunotherapies (Roche Innovation Center)
*Complementary models to study oncolytic virus immunotherapy (National Center for Tumor Diseases)
*Improving translational gap of preclinical outcomes through PKPD modelling (AstraZeneca)
Join this community to meet 100+ like-minded translational, in vivo and pharmacology scientists to discuss how to enhance predictiveness and translatability of your preclinical models.
Gold: Conference + 2 Workshops: GBP 3797.0,
Silver: Conference + 1 Workshop: GBP 3298.0,
Bronze: Conference Only: GBP 2799.0
Speakers: Sukhvinder Sidhu, Global Head of Pharmacology, Sanofi, Neta Moskovits, Head of The Translational Cancer Research Lab, Rabin Medical Center, Anita Seshire, Head of Laboratory Cellular Pharmacology and Translational Innovation Platform Oncology, Merck Healthcare KGaA, Roberto Speck, Principal Investigator, University of Zurich, Jennifer Walker, Principal Scientist, MedImmune, Sara Colombetti, Head of Global Oncology Discovery Pharmacology and Group Leader, Roche Innovation Center, Ludovic Bigot, Project Manager, Institut Gustave Roussy, Olivia Harris, Post-Doctoral Fellow, MedImmune, Herve Luche, Director, Scientific Immunophenotyping Unit, CIPHE - Centre D’ImmunophENomique, Niina Veitonmaki, Director, In Vivo Immune-Oncology and Head of In Vivo Core, Molecular Partners AG, Paul McSheehy, Senior Scientist and Leader, Cancer Biology In Vivo and Translational Science Oncology, Basilea Pharmaceutica, James Yates, Principal Scientist, AstraZeneca, Rajendra Kumari, Global Head of Scientific Communications, Crown Bioscience, Ralph Gareus, Director Business Development Europe, The Jackson Laboratory, Jean Viallet, Chief Executive Officer, INOVOTION, Maryland Franklin, Vice President Scientific Development, MI Bioresearch, Tseten Jamling, Vice President of Research and Development, Hera Labs Inc. , Kader Thiam, Vice President of Transgenic Technologies, genOway, Gabri Van Der Pluijm, Head of Urology Research Laboratory, Leiden University, Hitesh Mistry, Clinical Pharmacometrics, Biostatistics, Data Science Senior Research Fellow, University of Manchester, Tao You, Pharmacokinetic and Pharmacodynamics Modeller and Data Scientist, Beyond Consulting Ltd, Krzysztof Wicher, Director, Pharmacology and Translational Sciences, Kymab, Christine Engeland, Cancer Researcher, National Center for Tumor Diseases, John Prime, Principal Consultant, OncoBioinformatics Consulting
Venue Details: DoubleTree by Hilton Hotel London - Tower of London